{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.70","upperLimit":"26.26","value":"13.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"}],"units":"Participants"}],"description":"CCR rate was defined as percentage of participants with CR and CRc. CR was defined as normalization of blast percentage (≤ 5%); normalization of neutrophil count (≥ 1000/μL) and platelet count (≥ 100,000/μL); absence of leukemic blasts; 100% clearance of all skin lesions from baseline; no new lesions in participants without lesions at baseline; nodal masses regression to normal size on CT; and spleen and liver not palpable and nodules disappeared. CRc was defined as normalization of blast percentage (≤ 5%); normalization of neutrophil count (≥ 1000/μL) and platelet count (≥ 100,000/μL); absence of leukemic blasts; marked clearance of all skin lesions from baseline, residual hyperpigmentation or abnormality with BPDCN identified on biopsy (or no biopsy performed); nodal masses regression to normal size on CT; and spleen and liver not palpable and nodules disappeared.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received IMGN632 via IV infusion on Day 1 of each 21-day cycle.","id":"OG000","title":"BPDCN Participants - Schedule A: IMGN632 0.045 mg/kg"}],"paramType":"NUMBER","populationDescription":"mITT Population included all participants who were eligible based on the screening criteria and who received at least 1 dose of study drug. Here, 'Overall number of participants analyzed' = R/R BPDCN participants. Per protocol, this endpoint evaluated only R/R BPDCN Participants, all of whom were in arm Schedule A: IMGN632 0.045 mg/kg.","reportingStatus":"POSTED","timeFrame":"Up to approximately 81 months","title":"CCR Rate As Assessed by Investigator in Participants With Relapsed/Refractory (R/R) BPDCN","type":"SECONDARY","unitOfMeasure":"percentage of participants"}